These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


192 related items for PubMed ID: 8698311

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Proliferative activity is a significant prognostic factor in male breast carcinoma.
    Pich A, Margaria E, Chiusa L.
    Am J Pathol; 1994 Aug; 145(2):481-9. PubMed ID: 7519830
    [Abstract] [Full Text] [Related]

  • 3. Nuclear morphometry in male breast carcinoma: association with cell proliferative activity, oncogene expression, DNA content and prognosis.
    Chiusa L, Margaria E, Pich A.
    Int J Cancer; 2000 Nov 20; 89(6):494-9. PubMed ID: 11102893
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Appraisal of intratumoral microvessel density, MIB-1 score, DNA content, and p53 protein expression as prognostic indicators in patients with locally confined renal cell carcinoma.
    Gelb AB, Sudilovsky D, Wu CD, Weiss LM, Medeiros LJ.
    Cancer; 1997 Nov 01; 80(9):1768-75. PubMed ID: 9351546
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prognostic significance of DNA ploidy pattern and nucleolar organizer regions (AgNOR) in colorectal carcinoma.
    Eminović-Behrem S, Trobonjaca Z, Petrovecki M, Dobi-Babić R, Dujmović M, Jonjić N.
    Croat Med J; 2000 Jun 01; 41(2):154-8. PubMed ID: 10853043
    [Abstract] [Full Text] [Related]

  • 11. Inverted urothelial papilloma: is ploidy, MIB-1 proliferative activity, or p53 protein accumulation predictive of urothelial carcinoma?
    Cheville JC, Wu K, Sebo TJ, Cheng L, Riehle D, Lohse CM, Shane V.
    Cancer; 2000 Feb 01; 88(3):632-6. PubMed ID: 10649258
    [Abstract] [Full Text] [Related]

  • 12. Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder.
    Pich A, Chiusa L, Formiconi A, Galliano D, Bortolin P, Comino A, Navone R.
    Cancer; 2002 Aug 15; 95(4):784-90. PubMed ID: 12209722
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. DNA ploidy pattern and cell cycle stage of tumor cells in soft-tissue sarcomas: clinical implications.
    Kuratsu S, Tomita Y, Myoui A, Uchida A, Ono K, Aozasa K.
    Oncology; 1995 Aug 15; 52(5):363-70. PubMed ID: 7637952
    [Abstract] [Full Text] [Related]

  • 15. Prognostic value of ploidy and proliferation markers in renal cell carcinoma.
    Tannapfel A, Hahn HA, Katalinic A, Fietkau RJ, Kühn R, Wittekind CW.
    Cancer; 1996 Jan 01; 77(1):164-71. PubMed ID: 8630925
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Prognostic significance of ploidy, MIB-1 proliferation marker, and p53 in renal cell carcinoma.
    Kramer BA, Gao X, Davis M, Hall M, Holzbeierlein J, Tawfik O.
    J Am Coll Surg; 2005 Oct 01; 201(4):565-70. PubMed ID: 16183495
    [Abstract] [Full Text] [Related]

  • 18. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases.
    Blom R, Guerrieri C, Stâl O, Malmström H, Simonsen E.
    Gynecol Oncol; 1998 Jan 01; 68(1):54-61. PubMed ID: 9454661
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival.
    Pich A, Margaria E, Chiusa L.
    J Clin Oncol; 2000 Aug 01; 18(16):2948-56. PubMed ID: 10944127
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 10.